Elevar Therapeutics (previously known as LSK BioPharma) is a pharmaceutical company. It specializes in the clinical development of therapies for unmet medical needs in cancer. It develops two proprietary drug candidates: rivoceranib (Apatinib), a VEGFR-2 inhibitor, which dealing with a variety of solid tumors and a BTK/JAK3 inhibitor with the potential to treat hematologic malignancies and rheumatoid arthritis as an immunosuppressive agent.